Compare · HOWL vs JNJ
HOWL vs JNJ
Side-by-side comparison of Werewolf Therapeutics Inc. (HOWL) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HOWL and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $658.24B, about 15218.3x HOWL ($43.3M).
- Over the past year, HOWL is down 32.5% and JNJ is up 54.0% - JNJ leads by 86.5 points.
- JNJ has been more active in the news (11 items in the past 4 weeks vs 5 for HOWL).
- JNJ has more recent analyst coverage (25 ratings vs 6 for HOWL).
- Company
- Werewolf Therapeutics Inc.
- Johnson & Johnson
- Price
- $0.93+4.60%
- $272.00-0.45%
- Market cap
- $43.3M
- $658.24B
- 1M return
- +105.78%
- +1.96%
- 1Y return
- -32.47%
- +54.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 11
- Recent ratings
- 6
- 25
Werewolf Therapeutics Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest HOWL
- SEC Form 425 filed by Werewolf Therapeutics Inc.
- Werewolf Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
- Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
- SEC Form 8-K filed by Werewolf Therapeutics Inc.
- SEC Form 10-Q filed by Werewolf Therapeutics Inc.
- Werewolf Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
- Director Evnin Luke sold $44,749 worth of shares (143,199 units at $0.31) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Werewolf Therapeutics Inc.
Latest JNJ
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- CEO and Chairman of the Board Duato Joaquin sold $12,515,010 worth of shares (48,480 units at $258.15), decreasing direct ownership by 15% to 275,967 units (SEC Form 4)
- EVP, Chief Legal Officer Forminard Elizabeth exercised 9,344 shares at a strike of $131.94 and sold $4,090,960 worth of shares (15,918 units at $257.00), decreasing direct ownership by 28% to 16,994 units (SEC Form 4)
- SEC Form 13F-HR filed by Johnson & Johnson
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One